In this article, the possible involvement of flad‐1 gene in neuromuscular function in C. elegans has been experimentally approached and the molecular rationale for Rf therapy in MADD/LSMFLAD further deal with. This evidence concerns the gene FLAD1 and multiple acyl-CoA dehydrogenase deficiency.